In summary, we validated five highly expressed proteins as specific targets for different tumour mutational backgrounds: CLIC3, CRABP2, and GMDS for AKT1E17K/TRAF7 tumours, CD44 for KLF4K409Q/TRAF7 tumours and ANXA3 for NF2−/− tumours. Here, CD44 is linked to neoplasm.